Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon, Charles G. Drake, Howard I. Scher, Karim Fizazi, Alberto Bossi, Alfons J.M. Van den Eertwegh, Michael Krainer, Nadine Houede, Ricardo Santos, Hakim Mahammedi, Siobhan Ng, Michele Maio, Fabio A. Franke, Santhanam Sundar, Neeraj Agarwal, Andries M. Bergman, Tudor E. Ciuleanu, Ernesto Korbenfeld, Lisa Sengeløv, Steinbjorn HansenChristopher Logothetis, Tomasz M. Beer, M. Brent McHenry, Paul Gagnier, David Liu, Winald R. Gerritsen
Dive into the research topics of 'Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial'. Together they form a unique fingerprint.